Another US Stelara Settlement Arrives, This Time For Fresenius And Formycon

Deal With Johnson & Johnson Allows US Biosimilar Ustekinumab Entry In 2025

 
• By Dave Wallace

A third settlement has been struck allowing a Stelara biosimilar to hit the US market in 2025, with partners Fresenius and Formycon agreeing terms with Johnson & Johnson that offer a launch date slightly later than previous settlers.

Red jigsaw pieces spelling out '2025'
The pieces are starting to fall into place for a series of ustekinumab biosimilar launches in the US in 2025 • Source: Shutterstock

More from Deals

More from Business